Mithra Pharmaceuticals: MITHRA'S NORTH AMERICAN ADVISORY BOARD FOR DONESTA® WILL MEET IN MIAMI, FLORIDA THE 20TH- 21ST JANUARY 2017

PRESS RELEASE

Mithra's North american Advisory Board for Donesta® will meet in miami, Florida the 20^th- 21^st January 2017

• Mithra has set up scientific advisory boards composed of international experts to support the development of Donesta®, its product candidate for menopause based on Estetrol (E4).
   
• The North American scientific advisory board, set up by Mithra, is aiming at gathering additional development guidance from international experts in the menopause field.

Liège, Belgium, 12 January 2017 - In order to support the development programme and to prepare its product candidate for a future introduction on the market, Mithra has set up a North American advisory committee. Composed of 7 acknowledged menopause experts from the USA and Canada, this committee will especially advise Mithra on the clinical relevance and the potential added value of E4 based product candidate for the treatment of vasomotor symptoms. The committee will work with Mithra to challenge the current and future development plan with the needs of the community at large.

This meeting will be chaired by Prof. Jean-Michel Foidart, member of Mithra's scientific committee.

François Fornieri, CEO of Mithra Pharmaceuticals: "We are extremely proud that we've been able to bring top tier Opinion Leaders together to help us with our development plan which is a key objective for Mithra. The interest these international experts show in taking part in this meeting reflects the continuous and growing need for safe and effective solutions in the menopause field. We expect our product candidate will bring more choices to women and hope it will allow to address the unmet medical needs they are confronted to".

A second Pan-European advisory board meeting will be organized in Lisboa, Portugal in February 2017 to pursue this world market analysis and support the development plans in the EU.

For more information, please contact:

Press

Julie Dessart
Chief Communication Officer
+32 4 349 28 22 / +32 475 86 41 75
[email protected]

Investor Relations

François Fornieri, CEO
+32 4 349 28 22
[email protected]

Consilium Strategic Communications
Jonathan Birt, Sue Stuart, Hendrik Thys
[email protected]
+44 2 037 095 700

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.

Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com